Erratum: Screening for hepatitis C virus infection in adolescents and adults: updated evidence report and systematic review for the US Preventive Services Task Force (JAMA - Journal of the American Medical Association (2020) DOI: 10.1001/jama.2019.20788);Screening for Hepatitis C Virus Infection in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

JAMA - Journal of the American Medical Association

Volumn 323, Issue 10, 2020, Pages 976-991

  Chou, Roger ^a   Dana, Tracy ^a   Fu, Rongwei ^a   Zakher, Bernadette ^a   Wagner, Jesse ^a   Ramirez, Shaun ^a   Grusing, Sara ^a   Jou, Janice H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ALL CAUSE MORTALITY; ANTIVIRAL THERAPY; ARTICLE; CANCER RISK; CLINICAL OUTCOME; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFECT; FUNCTIONAL ASSESSMENT; HEPATITIS C; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCREENING TEST; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 85081625023     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2020.3544     Document Type: Erratum

References (116)

1. Hofmeister MG, Rosenthal EM, Barker LK, Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019; 69 (3): 1020-1031. doi: 10.1002/hep.30297 30398671
2. Centers for Disease Control and Prevention (CDC). Surveillance for viral hepatitis-United States, 2016. Updated October 1, 2018. Accessed June 25, 2019. https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm
3. Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017; 1 (2): 87-98. doi: 10.1002/hep4.1028 29404447
4. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 159 (5): 349-357. doi: 10.7326/0003-4819-159-5-201309030-00672 23798026
5. Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013; 158 (2): 101-108. doi: 10.7326/0003-4819-158-2-201301150-00574 23183613
6. Chou R, Cottrell E, Wasson N, Rahman B, Guise J-M. Screening for Hepatitis C Virus Infection in Adults: Comparative Effectiveness Review No. 69. Agency for Healthcare Research and Quality; 2012. AHRQ publication 12(13)-EHC090-EF.
7. Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R. Treatment for Hepatitis C Virus Infection in Adults. Agency for Healthcare Research and Quality; 2012.
8. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 2013; 158 (2): 114-123. doi: 10.7326/0003-4819-158-2-201301150-00576 23437439
9. Chou R, Hartung D, Rahman B, Wasson N, Cottrell E, Fu R. Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness Review No. 76. Agency for Healthcare Research and Quality; 2012. AHRQ publication 12(13)-EHC113-EF.
10. American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C: overview of cost, reimbursement, and cost-effectiveness considerations for hepatitis C treatment regimens. Updated September 21, 2017. Accessed June 25, 2019. https://www.hcvguidelines.org/evaluate/cost
11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21 (11): 1539-1558. doi: 10.1002/sim.1186 12111919
12. Dore GJ, Conway B, Luo Y, Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials. J Hepatol. 2016; 64 (1): 19-28. doi: 10.1016/j.jhep.2015.08.015 26321288
13. Feld JJ, Kowdley KV, Coakley E, Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370 (17): 1594-1603. doi: 10.1056/NEJMoa1315722 24720703
14. Feld JJ, Jacobson IM, Hézode C,; ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015; 373 (27): 2599-2607. doi: 10.1056/NEJMoa1512610 26571066
15. Foster GR, Afdhal N, Roberts SK,; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015; 373 (27): 2608-2617. doi: 10.1056/NEJMoa1512612 26575258
16. Kumada H, Chayama K, Rodrigues L Jr, Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015; 62 (4): 1037-1046. doi: 10.1002/hep.27972 26147154
17. Wei L, Jia JD, Wang FS,; C-CORAL Investigators. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019; 34 (1): 12-21. 30311701
18. Abergel A, Metivier S, Samuel D, Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016; 64 (4): 1049-1056. doi: 10.1002/hep.28706 27351341
19. Abergel A, Asselah T, Metivier S, Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016; 16 (4): 459-464. doi: 10.1016/S1473-3099(15)00529-0 26803446
20. Afdhal N, Zeuzem S, Kwo P,; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370 (20): 1889-1898. doi: 10.1056/NEJMoa1402454 24725239
21. Ahmed OA, Kaisar HH, Badawi R, Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist. 2018; 11: 295-298. doi: 10.2147/IDR.S153060 29535545
22. Andreone P, Colombo MG, Enejosa JV, ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147 (2): 359-365. doi: 10.1053/j.gastro.2014.04.045 24818763
23. Asselah T, Kowdley KV, Zadeikis N, Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018; 16 (3): 417-426. doi: 10.1016/j.cgh.2017.09.027 28951228
24. Asselah T, Lee SS, Yao BB, Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019; 4 (1): 45-51. doi: 10.1016/S2468-1253(18)30341-8 30393106
25. Brown A, Hézode C, Zuckerman E,; C-SCAPE Study Investigators. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: the C-SCAPE study. J Viral Hepat. 2018; 25 (5): 457-464. doi: 10.1111/jvh.12801 29152828
26. Chayama K, Suzuki F, Karino Y, Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018; 53 (4): 557-565. doi: 10.1007/s00535-017-1391-5 28948366
27. Chuang WL, Chien RN, Peng CY, Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. J Gastroenterol Hepatol. 2016; 31 (7): 1323-1329. doi: 10.1111/jgh.13305 26841930
28. Everson GT, Towner WJ, Davis MN, Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015; 163 (11): 818-826. doi: 10.7326/M15-1000 26551051
29. Ferenci P, Bernstein D, Lalezari J,; PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370 (21): 1983-1992. doi: 10.1056/NEJMoa1402338 24795200
30. Gane EJ, Hyland RH, An D, Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015; 149 (6): 1454-1461. doi: 10.1053/j.gastro.2015.07.063 26261007
31. Grebely J, Dalgard O, Conway B,; SIMPLIFY Study Group. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018; 3 (3): 153-161. doi: 10.1016/S2468-1253(17)30404-1 29310928
32. Grebely J, Conway B, Cunningham EB,; D3FEAT Study Group. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. Int J Drug Policy. 2018; 62: 94-103. doi: 10.1016/j.drugpo.2018.10.004 30384028
33. Hézode C, Asselah T, Reddy KR, Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015; 385 (9986): 2502-2509. doi: 10.1016/S0140-6736(15)60159-3 25837829
34. Kowdley KV, Gordon SC, Reddy KR,; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370 (20): 1879-1888. doi: 10.1056/NEJMoa1402355 24720702
35. Kowdley KV, Lawitz E, Poordad F, Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014; 370 (3): 222-232. doi: 10.1056/NEJMoa1306227 24428468
36. Kumada H, Suzuki Y, Karino Y, The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol. 2017; 52 (4): 520-533. doi: 10.1007/s00535-016-1285-y 27873094
37. Kwo P, Gitlin N, Nahass R, Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 2016; 64 (2): 370-380. doi: 10.1002/hep.28467 26799692
38. Lalezari J, Sullivan JG, Varunok P, Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015; 63 (2): 364-369. doi: 10.1016/j.jhep.2015.03.029 25839406
39. Lawitz E, Sulkowski MS, Ghalib R, Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384 (9956): 1756-1765. doi: 10.1016/S0140-6736(14)61036-9 25078309
40. Lawitz E, Poordad FF, Pang PS, Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014; 383 (9916): 515-523. doi: 10.1016/S0140-6736(13)62121-2 24209977
41. Lawitz E, Makara M, Akarca US, Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology. 2015; 149 (4): 971-80. doi: 10.1053/j.gastro.2015.07.001 26170136
42. Lim YS, Ahn SH, Lee KS, A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatol Int. 2016; 10 (6): 947-955. doi: 10.1007/s12072-016-9726-5 27198664
43. Nelson DR, Cooper JN, Lalezari JP,; ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61 (4): 1127-1135. doi: 10.1002/hep.27726 25614962
44. Pianko S, Flamm SL, Shiffman ML, Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015; 163 (11): 809-817. doi: 10.7326/M15-1014 26551263
45. Poordad F, Felizarta F, Asatryan A, Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017; 66 (2): 389-397. doi: 10.1002/hep.29081 28128852
46. Pott-Junior H, Bricks G, Grandi G, Figueiredo Senise J, Castelo Filho A. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. Clin Microbiol Infect. 2019; 25 (3): 365-371. doi: 10.1016/j.cmi.2018.06.007 29906601
47. Sperl J, Horvath G, Halota W, Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III randomized controlled trial. J Hepatol. 2016; 65 (6): 1112-1119. doi: 10.1016/j.jhep.2016.07.050 27542322
48. Sulkowski MS, Gardiner DF, Rodriguez-Torres M,; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370 (3): 211-221. doi: 10.1056/NEJMoa1306218 24428467
49. Sulkowski M, Hezode C, Gerstoft J, Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385 (9973): 1087-1097. doi: 10.1016/S0140-6736(14)61793-1 25467560
50. Toyoda H, Chayama K, Suzuki F, Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018; 67 (2): 505-513. doi: 10.1002/hep.29510 28865152
51. Waked I, Shiha G, Qaqish RB, Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016; 1 (1): 36-44. doi: 10.1016/S2468-1253(16)30002-4 28404110
52. Wei L, Xie Q, Hou JL, Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatol Int. 2018; 12 (2): 126-132. doi: 10.1007/s12072-018-9856-z 29637511
53. Wei L, Lim SG, Xie Q, Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019; 4 (2): 127-134. doi: 10.1016/S2468-1253(18)30343-1 30555048
54. Zeuzem S, Ghalib R, Reddy KR, Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163 (1): 1-13. doi: 10.7326/M15-0785 25909356
55. Zeuzem S, Foster GR, Wang S, Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018; 378 (4): 354-369. doi: 10.1056/NEJMoa1702417 29365309
56. Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat. 2019; 26 (2): 263-270. doi: 10.1111/jvh.13032 30380158
57. Balistreri WF, Murray KF, Rosenthal P, The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017; 66 (2): 371-378. doi: 10.1002/hep.28995 27997679
58. El-Karaksy H, Mogahed EA, Abdullatif H, Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir. J Pediatr Gastroenterol Nutr. 2018; 67 (5): 626-630. doi: 10.1097/MPG.0000000000002101 30216203
59. Jonas MM, Squires RH, Rhee SM, Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic HCV: part 1 of the DORA study. Hepatology. 2020; 71 (2): 456-462. doi: 10.1002/hep.30840 31254392
60. Leung DH, Wirth S, Yao BB, Ombitasvir/paritaprevir/ritonavir with or without dasabuvir and with or without ribavirin for adolescents with HCV genotype 1 or 4. Hepatol Commun. 2018; 2 (11): 1311-1319. doi: 10.1002/hep4.1250 30411078
61. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017; 66 (4): 1102-1110. doi: 10.1002/hep.29278 28543053
62. Yakoot M, El-Shabrawi MH, AbdElgawad MM, Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018; 67 (1): 86-89. doi: 10.1097/MPG.0000000000001968 29570560
63. Arase Y, Ikeda K, Suzuki F, Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007; 50 (1): 16-23. doi: 10.1159/000096308 17164553
64. Asahina Y, Tsuchiya K, Tamaki N, Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010; 52 (2): 518-527. doi: 10.1002/hep.23691 20683951
65. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011; 9 (6): 509-516. doi: 10.1016/j.cgh.2011.03.004 21397729
66. Butt AA, Yan P, Simon TG, Abou-Samra AB. Effect of paritaprevir/ritonavir/ombitasvir/dasabuvir and ledipasvir/sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: results from ERCHIVES. Clin Infect Dis. 2017; 65 (6): 1006-1011. doi: 10.1093/cid/cix364 28903508
67. Butt AA, Yan P, Shuaib A, Abou-Samra AB, Shaikh OS, Freiberg MS. Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events. Gastroenterology. 2019; 156 (4): 987-996. doi: 10.1053/j.gastro.2018.11.022 30445009
68. Carrat F, Fontaine H, Dorival C,; French ANRS CO22 Hepather Cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019; 393 (10179): 1453-1464. doi: 10.1016/S0140-6736(18)32111-1 30765123
69. Cozen ML, Ryan JC, Shen H, Nonresponse to interferon- based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One. 2013; 8 (4):
70. Dieperink E, Pocha C, Thuras P, Knott A, Colton S, Ho SB. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014; 59 (4): 872-880. doi: 10.1007/s10620-014-3050-5 24532254
71. Dohmen K, Kawano A, Takahashi K, The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C. Hepatogastroenterology. 2013; 60 (128): 2034-2038. 24719946
72. El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014; 109 (9): 1427-1435. doi: 10.1038/ajg.2014.214 25070058
73. Ikeda K, Saitoh S, Arase Y, Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29 (4): 1124-1130. doi: 10.1002/hep.510290439 10094956
74. Imai Y, Kawata S, Tamura S,; Osaka Hepatocellular Carcinoma Prevention Study Group. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998; 129 (2): 94-99. doi: 10.7326/0003-4819-129-2-199807150-00005 9669992
75. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003; 38 (2): 493-502. doi: 10.1053/jhep.2003.50329 12883494
76. Innes HA, Hutchinson SJ, Allen S,; Hepatitis C Clinical Database Monitoring Committee. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011; 54 (5): 1547-1558. doi: 10.1002/hep.24561 22045672
77. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018; 68 (1): 25-32. doi: 10.1016/j.jhep.2017.08.030 29524530
78. Izumi N, Yasuhiro A, Kurosaki M, Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C: is it possible to reduce the incidence by ribanirin and IFN combination therapy? Intervirology. 2005; 48 (1): 59-63. doi: 10.1159/000082096 15785091
79. Kasahara A, Hayashi N, Mochizuki K,; Osaka Liver Disease Study Group. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998; 27 (5): 1394-1402. doi: 10.1002/hep.510270529 9581697
80. Kasahara A, Tanaka H, Okanoue T, Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 2004; 11 (2): 148-156. doi: 10.1046/j.1365-2893.2003.00481.x 14996350
81. Kurokawa M, Hiramatsu N, Oze T, Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res. 2009; 39 (5): 432-438. doi: 10.1111/j.1872-034X.2008.00477.x 19207583
82. Lee SH, Jin YJ, Shin JY, Lee JW. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs. Medicine (Baltimore). 2017; 96 (1):
83. Li DK, Ren Y, Fierer DS, The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study. Hepatology. 2018; 67 (6): 2244-2253. doi: 10.1002/hep.29707 29205416
84. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012; 27 (2): 291-299. doi: 10.1111/j.1440-1746.2011.06871.x 21793911
85. Okanoue T, Itoh Y, Kirishima T, Transient biochemical response in interferon therapy decreases the development of hepatocellular carcinoma for five years and improves the long-term survival of chronic hepatitis C patients. Hepatol Res. 2002; 23 (1): 62-77. doi: 10.1016/S1386-6346(02)00016-5 12084557
86. Osaki Y, Ueda Y, Marusawa H, Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study. J Gastroenterol. 2012; 47 (4): 444-451. doi: 10.1007/s00535-011-0505-8 22105231
87. Singal AG, Dharia TD, Malet PF, Alqahtani S, Zhang S, Cuthbert JA. Long-term benefit of hepatitis C therapy in a safety net hospital system: a cross-sectional study with median 5-year follow-up. BMJ Open. 2013; 3 (9):
88. Sinn DH, Paik SW, Kang P, Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int. 2008; 28 (10): 1363-1369. doi: 10.1111/j.1478-3231.2008.01860.x 18710426
89. Tanaka H, Tsukuma H, Kasahara A, Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000; 87 (5): 741-749. doi: 10.1002/1097-0215(20000901)87:5<741::AID-IJC18>3.0.CO;2-B 10925370
90. Tateyama M, Yatsuhashi H, Taura N, Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011; 46 (1): 92-100. doi: 10.1007/s00535-010-0293-6 20711614
91. Tseng CW, Chang TT, Tzeng SJ, Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. Clin Interv Aging. 2016; 11: 327-334. doi: 10.2147/CIA.S97242 27051280
92. Yoshida H, Shiratori Y, Moriyama M,; IHIT Study Group. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999; 131 (3): 174-181. doi: 10.7326/0003-4819-131-3-199908030-00003 10428733
93. Yoshida H, Arakawa Y, Sata M, Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002; 123 (2): 483-491. doi: 10.1053/gast.2002.34785 12145802
94. Yu ML, Lin S-M, Chuang W-L, A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther. 2006; 11 (8): 985-994. 17302368
95. Younossi ZM, Stepanova M, Feld J, Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017; 15 (3): 421-430. doi: 10.1016/j.cgh.2016.10.037 27847279
96. Younossi ZM, Stepanova M, Afdhal N, Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015; 63 (2): 337-345. doi: 10.1016/j.jhep.2015.03.014 25795586
97. Younossi ZM, Stepanova M, Schwarz KB, Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat. 2018; 25 (4): 354-362. doi: 10.1111/jvh.12830 29193603
98. Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health. 2012; 102 (11): e101-e106. doi: 10.2105/AJPH.2011.300488 22813094
99. Ng X, Nwankwo C, Arduino JM, Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir. Patient Prefer Adherence. 2018; 12: 2631-2638. doi: 10.2147/PPA.S172732 30587935
100. Younossi ZM, Stepanova M, Balistreri W, Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr. 2018; 66 (1): 112-116. doi: 10.1097/MPG.0000000000001754 28957984
101. Azzaroli F, Accogli E, Nigro G, Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol. 2004; 10 (21): 3099-3102. doi: 10.3748/wjg.v10.i21.3099 15457551
102. Bernardinello E, Cavalletto L, Chemello L,; TVVH Study Group. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. Hepatogastroenterology. 1999; 46 (30): 3216-3222. 10626189
103. Bruix J, Poynard T, Colombo M,; EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011; 140 (7): 1990-1999. doi: 10.1053/j.gastro.2011.03.010 21419770
104. Fartoux L, Degos F, Trépo C, Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol. 2007; 5 (4): 502-507. doi: 10.1016/j.cgh.2006.10.016 17261383
105. Nishiguchi S, Shiomi S, Nakatani S, Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001; 357 (9251): 196-197. doi: 10.1016/S0140-6736(00)03595-9 11213099
106. Valla DC, Chevallier M, Marcellin P, Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999; 29 (6): 1870-1875. doi: 10.1002/hep.510290616 10347132
107. Lok AS, Everhart JE, Wright EC,; HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011; 140 (3): 840-849. doi: 10.1053/j.gastro.2010.11.050 21129375
108. Soga K, Shibasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology. 2005; 52 (64): 1154-1158. 16001651
109. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017; 166 (9): 637-648. doi: 10.7326/M16-2575 28319996
110. Jakobsen JC, Nielsen EE, Feinberg J, Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017; 6:
111. Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018; 67 (11): 2025-2034. doi: 10.1136/gutjnl-2018-316234 29703790
112. Bang CS, Song IH. Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis. BMC Gastroenterol. 2017; 17 (1): 46. doi: 10.1186/s12876-017-0606-9 28376711
113. Waziry R, Hajarizadeh B, Grebely J, Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017; 67 (6): 1204-1212. doi: 10.1016/j.jhep.2017.07.025 28802876
114. Indolfi G, Serranti D, Resti M. Direct-acting antivirals for children and adolescents with chronic hepatitis C. Lancet Child Adolesc Health. 2018; 2 (4): 298-304. doi: 10.1016/S2352-4642(18)30037-3 30169301
115. Yek C, de la Flor C, Marshall J, Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. BMC Med. 2017; 15 (1): 204. doi: 10.1186/s12916-017-0969-3 29151365
116. Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology. 2017; 65 (2): 426-438. doi: 10.1002/hep.28901 27775854